EGFR and non-small cell lung carcinoma: The S-adenosylhomocysteine hydrolase inhibitor DZnep proved to efficiently target the enzyme and to impair tumor growth in a subset of NSCLC genotypes with epidermal growth factor receptor (EGFR) or BRG1 mutations when combined with the topoisomerase II inhibitor etoposide (Fillmore et al., 2015).